Abstract: An example electric lighting system includes a lighting device that includes a housing including a lighting element and a power device holding portion. The power device holding portion includes a cavity. The cavity includes a first and a second electrical contact disposed within the cavity. The power device includes a third and a fourth electrical contact. The power device includes a coupling component. The coupling component is removably couplable to the power device holding portion such that an electrical communication is established when the power device is inserted into the cavity at any rotational position relative to the lighting device about a shared central axis. The power device is operable to power the lighting device through the electrical communication. The electrical communication is established between the first electrical contact and the third electrical contact and between the second electrical contact and the fourth electrical contact.

Abstract: Antibodies and compositions against Claudin 18.2 and uses thereof are provided herein.

Abstract: A drive mechanism for a drug delivery device with a reduced operating loudness includes a dose selector, a housing, and a ratchet with a gear element comprising a plurality of gear teeth connected with the dose selector and a pawl element rotationally constrained to the housing comprising at least one pawl tooth. The at least one pawl tooth engages with the gear teeth and is located opposite to the gear teeth. One of the gear element and the pawl element moves forth and back relative to the other element of the gear and pawl elements along a first direction for de-engagement and re-engagement of the opposite gear teeth and at least one pawl tooth when the gear element rotates relative to the housing during dose setting using the dose selector. The pawl element and/or gear element comprises a noise reduction characteristic at a surface which dampens the noise produced.

Abstract: The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies, wherein the disease is facioscapulohumeral muscular dystrophy (FSHD). It also relates to use of such compounds, or to methods of use of such compounds.

Abstract: The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies. It also relates to use of such compounds, or to methods of use of such compounds.

Abstract: A drive mechanism for a drug delivery device with a reduced operating loudness includes a dose selector, a housing, and a ratchet with a gear element comprising a plurality of gear teeth connected with the dose selector and a pawl element rotationally constrained to the housing comprising at least one pawl tooth. The at least one pawl tooth engages with the gear teeth and is located opposite to the gear teeth. One of the gear element and the pawl element moves forth and back relative to the other element of the gear and pawl elements along a first direction for de-engagement and re-engagement of the opposite gear teeth and at least one pawl tooth when the gear element rotates relative to the housing during dose setting using the dose selector.

Abstract: The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies, wherein the disease is facioscapulohumeral muscular dystrophy (FSHD). It also relates to use of such compounds, or to methods of use of such compounds.

Abstract: A sense amplifier has a differential pair with two inputs and two outputs. The differential pair inputs can receive two analog input signals. The differential pair outputs are coupled with inputs of an amplifier with positive feedback, whose outputs are coupled with the sense amplifier outputs. Based on a clock signal, a first switch is configured for short circuiting an output signal on the sense amplifier output terminals. A second switch is configured for short circuiting a differential pair output signal. Third and fourth switches may short circuit the differential pair outputs to the supply voltage rail or the ground reference rail. The switches may include transistors, or transmission gates. The amplifier with positive feedback may include two cross-coupled inverters.

Abstract: The present invention relates to bicyclic tetrahydrothiazepine of formula (I), wherein R1 to R3, X1, X2 and R18 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising such compounds as well as their use as medicaments, especially in methods for the treatment or prevention of a neoplastic and/or infectious disease and in vitro methods.

Abstract: The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies, wherein the disease is facioscapulohumeral muscular dystrophy (FSHD). It also relates to use of such compounds, or to methods of use of such compounds.

Abstract: A block of logic gates has MOS transistors whose body terminals are connected with a body voltage rail and whose source terminals are connected with a logic reference voltage rail. The logic reference voltage rail is connected to the body voltage rail via a resistor. The resistor creates a negative feedback loop for leakage currents that stabilizes a reverse body bias voltage and reduces the influence of temperature, voltage, and process variations. The block may be NMOS, PMOS, or CMOS. In the case of CMOS, there are two body voltage rails, powered by a voltage source, two logic reference voltage rails, and two resistors. The reverse body bias voltages over the two resistors may be stabilized by decoupling capacitors. The two resistors may be trimmable. The resistors may be calibrated such that leakage currents are at a minimum value and the logic gates can switch just fast enough.

Abstract: A comparator circuit has a sense amplifier with a differential pair, a voltage excursion limiter, and a switch. The differential pair receives two analog input signals. Its differential outputs operate at a common mode voltage approximately half the supply voltage. The voltage limiter is coupled with one of the differential pair outputs. A capacitor may store comparison results. The switch energizes the differential pair and the voltage excursion limiter during a first phase of a clock, and de-energizes them during a second phase of the clock. During this phase, the comparator may provide the stored comparison result to an amplifier with positive feedback.

Abstract: The present invention relates to bicyclic tetrahydrothiazepine of formula (I), wherein R1 to R3, X1, X2 and R18 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising such compounds as well as their use as medicaments, especially in methods for the treatment or prevention of a neoplastic and/or infectious disease and in vitro methods.

Abstract: Waste management apparatus comprising; means for receiving and storing organic waste, processing means configured to process the organic waste into feedstock, and a programmable logic controller in communication with the processing means, wherein the programmable logic controller is configured to: determine values of one or more properties of the feedstock using the processing means, determine one or more new operational parameters of the processing means based on the determined values of the one or more properties of the feedstock, and output instructions to the processing means, wherein the instructions are based on the determined one or more new operational parameters.

Abstract: A block of logic gates has MOS transistors whose body terminals are connected with a body voltage rail and whose source terminals are connected with a logic reference voltage rail. The logic reference voltage rail is connected to the body voltage rail via a resistor. The resistor creates a negative feedback loop for leakage currents that stabilizes a reverse body bias voltage and reduces the influence of temperature, voltage, and process variations. The block may be NMOS, PMOS, or CMOS. In the case of CMOS, there are two body voltage rails, powered by a voltage source, two logic reference voltage rails, and two resistors. The reverse body bias voltages over the two resistors may be stabilized by decoupling capacitors. The two resistors may be trimmable. The resistors may be calibrated such that leakage currents are at a minimum value and the logic gates can switch just fast enough.

Abstract: A comparator circuit has a sense amplifier with a differential pair, a voltage excursion limiter, and a switch. The differential pair receives two analog input signals. Its differential outputs operate at a common mode voltage approximately half the supply voltage. The voltage limiter is coupled with one of the differential pair outputs. A capacitor may store comparison results. The switch energizes the differential pair and the voltage excursion limiter during a first phase of a clock, and de-energizes them during a second phase of the clock. During this phase, the comparator may provide the stored comparison result to an amplifier with positive feedback.

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain pyridine benzamide and pyrazine benzamide compounds (referred to herein as PDBA and PZBA compounds) which, inter alia, inhibit protein kinase D (PKD) (e.g., PKD1, PKD2, PKD3). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PKD, and in the treatment of diseases and conditions that are mediated by PKD, that are ameliorated by the inhibition of PKD, etc., including proliferative conditions such as cancer, etc.

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain amino-ethyl-amino-aryl (AEAA) compounds which, inter alia, inhibit protein kinase D (PKD) (e.g., PKD1, PKD2, PKD3). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PKD, and in the treatment of diseases and conditions that are mediated by PKD, that are ameliorated by the inhibition of PKD, etc., including proliferative conditions such as cancer, etc.